Urothelial Cancer Prediction Model Has High Sensitivity, Specificity
Model, which considers 10 genes from UroAmp uCGP test, had high sensitivity and specificity in two validation cohorts.
Diagnosis & Disease Information
UGN-101 Reviewed in Real-World Upper Tract Urothelial Cancer Setting
For patients with low-grade residual disease, complete response rate was 70 percent with UGN-101.
Nab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
Overall response rate 50 percent among 36 patients with platinum-refractory or cisplatin-ineligible advanced urothelial cancer.
Administration of Mitomycin Gel via PCNT Safe for Upper Tract Urothelial Carcinoma
Researchers sought to determine if antegrade administration of mitomycin gel via PCNT was safe and feasible in patients with upper tract urothelial carcinoma.
Enfortumab Vedotin Plus Pembrolizumab ‘Promising’ for Untreated Advanced Urothelial Carcinoma
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Cutaneous Adverse Effects Common With Enfortumab Vedotin for Urothelial Cancer
Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.
Glasgow Prognostic Score Predicts Adverse Pathology, Survival in UTUC
In a study, modified Glasgow prognostic score predicted nonorgan-confined disease and lymph node invasion at surgery.
UTUC Incidence Rising in The Netherlands
A study of 13,438 patients with upper tract urothelial carcinoma in The Netherlands found that the incidence of the cancer increased significantly from 1993 to 2017, with no improvement in survival except for those with metastatic disease.
Pathologic Stage at RNU Predicts Oncologic Outcomes in High-Grade UTUC
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Addition of Atezolizumab May Aid in Metastatic Urothelial Cancer
Phase 3 trial shows prolonged progression-free survival for atezolizumab plus platinum-based chemotherapy.
- Loading...
Loading...
Next post in Genitourinary Cancer
Loading... 
Loading...